Your session is about to expire
← Back to Search
Pembrolizumab + Sacituzumab tirumotecan for Non-Small Cell Lung Cancer
Study Summary
This trial aims to see if combining MK-2870 with pembrolizumab after surgery can effectively treat non-small cell lung cancer (NSCLC) in patients who did not have a complete
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What is the overall safety profile of MK-2870 in combination with Pembrolizumab for individuals?
"Based on the fact that this trial is classified as Phase 3, which indicates the presence of both efficacy and safety data from multiple rounds, our team at Power rates the safety of MK-2870 + Pembrolizumab as a 3 on a scale of 1 to 3."
What is the current number of participants being enrolled in this research investigation?
"Affirmative. Details provided on clinicaltrials.gov indicate that this investigation is actively seeking volunteers. The trial was initially posted on April 3rd, 2024, and the most recent update occurred on April 15th, 2024. A total of 780 participants are sought across three designated sites."
Are there any available positions for patients to participate in this clinical trial?
"Affirmative. The information on clinicaltrials.gov reveals that this research study is presently seeking volunteers to participate. Initially shared on April 3rd, 2024, the most recent update was made on April 15th of the same year. A total of 780 individuals are being sought across three designated locations for inclusion in this trial."
Share this study with friends
Copy Link
Messenger